{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.4","upperLimit":"99.5","value":"80"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"The ORR was defined as the percentage of participants with an OR per investigator. A participant was determined to have an OR if, based on the 2016 IMWG uniform response criteria, and achieved a sCR, CR, VGPR, or a PR. sCR: FLC ratio \\& absence of clonal cells in bone marrow by IC/IF. CR: negative immunofixation of serum \\& urine, disappearance of any STP, 5% plasma cells in bone marrow. VGPR: serum and UMP detectable by immunofixation but not on electrophoresis/ \\>= 90% reduction in SMP level+UMP level \\<100 mg/24 hour, PR: \\>=50% reduction of SMP \\& reduction in 24-hour urinary M-protein by \\>=90%/to \\<200 mg/24 hour. If SMP \\& UMP are unmeasurable, a ≥50% decrease in the difference between involved \\& uninvolved FLC levels were required in place of the M-protein criteria. In addition to above criteria, if present at baseline, \\>=50% reduction in the size of STP were also required.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received SEA-BCMA 1600 mg IV q2wk on Day 1 and 15 of each 28-day cycle, dexamethasone 40 mg orally or as an IV infusion on Day 1, 8, 15, and 22 and pomalidomide 4 mg orally, daily from Day 1 to 21 of each of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG000","title":"Part D: SEA-BCMA 1600 mg, Pomalidomide and Dexamethasone"}],"paramType":"NUMBER","populationDescription":"All treated participants analysis set included all treated participants who received any amount of SEA-BCMA.","reportingStatus":"POSTED","timeFrame":"From the first dose of study treatment until the first documented sCR or CR or PR or VGPR or new anti-cancer therapies or death, whichever occurred first (maximum up to 20 months)","title":"ORR as Per the IMWG Uniform Response Criteria: Part D","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}